Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study

Eva C. Rijkmans*, Annemieke Cats, Remi A. Nout, Desiree van den Bongard, Martijn Ketelaars, Jeroen Buijsen, Tom Rozema, Jan Huib Franssen, Laura A. Velema, Baukelien van Triest, Corrie A M Marijnen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: To evaluate the toxicity and efficacy of the combination of external beam radiation therapy (EBRT) followed by high-dose-rate endorectal brachytherapy (HDREBT) boost in elderly and medically inoperable patients with rectal cancer. Methods and Materials: A phase 1 dose-escalation study was performed. Treatment consisted of EBRT (13 × 3 Gy) followed by 3 weekly brachytherapy applications 6 weeks later. The HDREBT dose started at 5 Gy per fraction, increasing with 1 Gy per fraction if dose-limiting toxicity (DLT, defined as grade ≥3 proctitis

Original languageEnglish
Pages (from-to)908-917
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume98
Issue number4
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Dive into the research topics of 'Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study'. Together they form a unique fingerprint.

Cite this